29
Apr

Amgen’s regulatory team for talimogene laherparepvec (T-Vec) was grilled by a group of outside FDA experts who picked up on some major questions regarding the Phase III melanoma study that was used to back its new drug application. A vigorous defense of the drug, though, helped make a winning case for the therapy, which was ultimately supported by all but one member of the panel.

…read more

Source: FDA panel gives a thumb’s up to Amgen’s T-Vec for melanoma

    

0 No comments